Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Venous Thromboembolism 4Venous Thrombosis 2Pulmonary Embolism 2Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thrombosis 1Thromboembolism 1Sarcoma 1Ovarian Neoplasms 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × Fondaparinux × Clear all
NCT00381888 2017-12-28

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
44 enrolled 7 charts
GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Thromboembolism, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡